198 related articles for article (PubMed ID: 16384708)
1. Myoepithelial cell cocktail (p63+SMA) for the evaluation of sclerosing breast lesions.
Pavlakis K; Zoubouli C; Liakakos T; Messini I; Keramopoullos A; Athanassiadou S; Kafousi M; Stathopoulos EN
Breast; 2006 Dec; 15(6):705-12. PubMed ID: 16384708
[TBL] [Abstract][Full Text] [Related]
2. p63 Expression of clear myoepithelial cells in epithelial-myoepithelial carcinoma of the salivary gland: a useful marker for naked myoepithelial cells in cytology.
Kawahara A; Harada H; Yokoyama T; Kage M
Cancer; 2005 Aug; 105(4):240-5. PubMed ID: 15959915
[TBL] [Abstract][Full Text] [Related]
3. Phenotypic alterations in myoepithelial cells associated with benign sclerosing lesions of the breast.
Hilson JB; Schnitt SJ; Collins LC
Am J Surg Pathol; 2010 Jun; 34(6):896-900. PubMed ID: 20463570
[TBL] [Abstract][Full Text] [Related]
4. The usefulness of p63 as a marker of breast myoepithelial cells.
Batistatou A; Stefanou D; Arkoumani E; Agnantis NJ
In Vivo; 2003; 17(6):573-6. PubMed ID: 14758723
[TBL] [Abstract][Full Text] [Related]
5. Availability of CD10 immunohistochemistry as a marker of breast myoepithelial cells on paraffin sections.
Moritani S; Kushima R; Sugihara H; Bamba M; Kobayashi TK; Hattori T
Mod Pathol; 2002 Apr; 15(4):397-405. PubMed ID: 11950913
[TBL] [Abstract][Full Text] [Related]
6. Adenomyoepithelial tumours and myoepithelial carcinomas of the breast--a spectrum of monophasic and biphasic tumours dominated by immature myoepithelial cells.
Hungermann D; Buerger H; Oehlschlegel C; Herbst H; Boecker W
BMC Cancer; 2005 Jul; 5():92. PubMed ID: 16050957
[TBL] [Abstract][Full Text] [Related]
7. Distribution of p63, a novel myoepithelial marker, in fine-needle aspiration biopsies of the breast: an analysis of 82 samples.
Reis-Filho JS; Milanezi F; Amendoeira I; Albergaria A; Schmitt FC
Cancer; 2003 Jun; 99(3):172-9. PubMed ID: 12811858
[TBL] [Abstract][Full Text] [Related]
8. Myoepithelial cells in the differential diagnosis of complex benign and malignant breast lesions: an immunohistochemical study.
Gottlieb C; Raju U; Greenwald KA
Mod Pathol; 1990 Mar; 3(2):135-40. PubMed ID: 1691493
[TBL] [Abstract][Full Text] [Related]
9. Morphometric analysis and p63 improve the identification of myoepithelial cells in breast lesion cytology.
Aikawa E; Kawahara A; Kondo K; Hattori S; Kage M
Diagn Cytopathol; 2011 Mar; 39(3):172-6. PubMed ID: 21319317
[TBL] [Abstract][Full Text] [Related]
10. Antibodies targeting p63 react specifically in the cytoplasm of breast epithelial cells exhibiting secretory differentiation.
Bratthauer GL; Saenger JS; Strauss BL
Histopathology; 2005 Dec; 47(6):611-6. PubMed ID: 16324199
[TBL] [Abstract][Full Text] [Related]
11. Naked nuclei revisited: p63 Immunoexpression.
Reis-Filho JS; Albergaria A; Milanezi F; Amendoeira I; Schmitt FC
Diagn Cytopathol; 2002 Sep; 27(3):135-8. PubMed ID: 12203858
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical staining of papillary breast lesions.
Troxell ML; Masek M; Sibley RK
Appl Immunohistochem Mol Morphol; 2007 Jun; 15(2):145-53. PubMed ID: 17525625
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical distinction of invasive from noninvasive breast lesions: a comparative study of p63 versus calponin and smooth muscle myosin heavy chain.
Werling RW; Hwang H; Yaziji H; Gown AM
Am J Surg Pathol; 2003 Jan; 27(1):82-90. PubMed ID: 12502930
[TBL] [Abstract][Full Text] [Related]
14. The role of immunocytochemical markers in the differential diagnosis of proliferative and neoplastic lesions of the breast.
Joshi MG; Lee AK; Pedersen CA; Schnitt S; Camus MG; Hughes KS
Mod Pathol; 1996 Jan; 9(1):57-62. PubMed ID: 8821958
[TBL] [Abstract][Full Text] [Related]
15. Double immunostaining with p63 and high-molecular-weight cytokeratins distinguishes borderline papillary lesions of the breast.
Ichihara S; Fujimoto T; Hashimoto K; Moritani S; Hasegawa M; Yokoi T
Pathol Int; 2007 Mar; 57(3):126-32. PubMed ID: 17295644
[TBL] [Abstract][Full Text] [Related]
16. Fine-needle aspiration cytology of breast lesions: a review of cytological analysis using smooth muscle actin (SMA) immunostaining.
Sato S; Kijima H; Suto A; Yoshida H; Sato T; Shimbori M; Terasaki-Fukuzawa Y; Onoda N; Araki K; Tsuruno K; Takeshita T
Anticancer Res; 2003; 23(5b):4175-9. PubMed ID: 14666621
[TBL] [Abstract][Full Text] [Related]
17. p63 expression in benign and malignant breast lesions.
Stefanou D; Batistatou A; Nonni A; Arkoumani E; Agnantis NJ
Histol Histopathol; 2004 Apr; 19(2):465-71. PubMed ID: 15024707
[TBL] [Abstract][Full Text] [Related]
18. Nestin is expressed in the basal/myoepithelial layer of the mammary gland and is a selective marker of basal epithelial breast tumors.
Li H; Cherukuri P; Li N; Cowling V; Spinella M; Cole M; Godwin AK; Wells W; DiRenzo J
Cancer Res; 2007 Jan; 67(2):501-10. PubMed ID: 17234757
[TBL] [Abstract][Full Text] [Related]
19. False-positives in fine-needle aspiration cytology of breast disease can be reduced with p63 immunostaining--a preliminary report.
Nagao T; Bando Y; Sasa M; Morimoto T; Sano N; Hirose T; Tangoku A
Anticancer Res; 2006; 26(6B):4373-7. PubMed ID: 17201157
[TBL] [Abstract][Full Text] [Related]
20. Distribution of myoepithelial cells and basement membrane proteins in the normal breast and in benign and malignant breast diseases.
Gusterson BA; Warburton MJ; Mitchell D; Ellison M; Neville AM; Rudland PS
Cancer Res; 1982 Nov; 42(11):4763-70. PubMed ID: 6290045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
